• Cash and cash equivalents: €19.7 million as of June 30, 2022
• Net loss down 8% to €12.4m for the first half of 2022
Publication of adjusted financial results as of December 31, 2021
Paris (France), Cambridge (Massachusetts, USA), January 31, 2023, 08:00 CET –
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in the development of treatments aimed at slowing the degenerative processes associated with aging and improving the functional outcomes of patients suffering from age-related diseases. , including respiratory failure in patients suffering from COVID-19, publishes today its interim financial report for the 1st half of 2022 and its adjusted financial results as of December 31, 2021.